To identify the most pressing topics for industry leaders, Cardiovascular Business spoke to course director Cathie Biga, MSN, RN, about the agenda for the 2018 American College of Cardiology Cardiovascular Summit.

The FDA on Feb. 15 announced Stryker’s Trevo Retriever clot-removal device can be used up to 24 hours after stroke onset, mirroring the American Heart Association and American Stroke Association’s recently updated guidelines expanding the window for mechanical thrombectomy from 6 to 24 hours.

The FDA cleared Viz.ai’s clinical support tool on Feb. 13, allowing the software that alerts clinicians to the possibility of a stroke to be marketed in the United States.

For older patients with heart failure with preserved ejection fraction (HFpEF), systolic blood pressure (SBP) levels below 120 mm Hg—and even 130—are associated with worse short- and long-term cardiovascular outcomes, according to a study published online Feb. 14 in JAMA Cardiology.

Researchers have identified a gene, called MeXis, that helps remove cholesterol from blood vessels. Senior study author Peter Tontonoz, MD, PhD, and colleagues found mice lacking MeXis had nearly twice as many blockages in their blood vessels as those that had normal levels of the gene.